SciSparc (SPRC)

Its core drug-development segment focuses on cannabinoid molecules and combinations intended for approval by regulatory authorities. SciSparc’s research has been directed toward conditions involving the central nervous system, inflammation and other areas where existing therapies may be inadequate. As a clinical-stage company, its value depends on the quality of its intellectual property, the progress of its studies, the safety profile of its candidates and its ability to secure partners or capital for further development.

SciSparc also reports a commercial segment built around online sales of hemp-based consumer products. This business includes items such as hemp gummies, hemp oil capsules, topical gels, creams, detox products and beauty or hair-care products manufactured in the United States. The consumer products operation provides exposure to the wellness market, although it is distinct from the company’s regulated pharmaceutical pipeline.

What distinguishes SciSparc is its dual approach: it pursues prescription-grade cannabinoid medicines while also maintaining a presence in hemp-derived consumer products. The pharmaceutical side offers the potential upside of approved drug development, but carries the typical risks of clinical trials, regulation and funding needs. The consumer side gives the company a broader cannabinoid-related commercial footprint, subject to competitive pressures and changing rules around hemp and wellness products.